Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital investment and job creation. The latest initiative will further grow the company’s presence in the U.S., which currently hosts Gilead’s largest research, development, and manufacturing footprint globally. Advertisement: High Yield Savings Offers Earn up to 4.35% APY** with $5k balance View Offer Earn up to 4.00% APY with Savings Pods View Offer Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer Powered by Money.com - Yahoo may earn commission from the links above. The investment includes a fresh allocation of $11 billion for capital and operational expenditures in the U.S. This is in addition to a previously planned spend of $21 billion aimed at U.S. manufacturing and research & development through 2030. The combined investment is projected to generate an extra $11 billion in U.S. economic impact. Gilead’s forthcoming investment phase will finance the construction of three new advanced facilities, the upgrade of three existing sites to extend U.S. manufacturing and R&D capabilities, and the investment in new technology and advanced engineering initiatives. The additional $11 billion breaks down as follows: - $4 billion for capital projects, including labs and equipment. - $5 billion for technology, operations, and R&D site activities. - $2 billion for digital and advanced engineering initiatives. Furthermore, the investment is set to create approximately 800 new direct jobs and support over 2,200 indirect jobs by 2028. This move continues Gilead’s long-standing history of U.S. investment, having invested $15 billion over the past decade. It also underscores Gilead’s significant role in the U.S. biopharmaceutical industry, contributing to scientific innovation and providing solutions for patients. Related articles Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing Charles River to initiate a review amid Elliott stake - Is a sale next? Discover Financial Services lowered to Hold at Jefferies View Comments
Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...